Caveolin-1 regulates leucocyte behaviour in fibrotic lung disease

• Published in: Annals of the rheumatic diseases Vol. 69; no. 6; pp. 1220 - 1226
• Main Authors: Tourkina, Elena, Richard, Mathieu, Oates, James, Hofbauer, Ann, Bonner, Michael, Gööz, Pal, Visconti, Richard, Zhang, Jing, Znoyko, Sergei, Hatfield, Corey M, Silver, Richard M, Hoffman, Stanley
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group Ltd and European League Against Rheumatism 01.06.2010; BMJ Publishing Group; Elsevier Limited
• Subjects: Adult; Aged; Animals; Autoimmune diseases; Biological and medical sciences; Bleomycin; Caveolin 1 - blood; Caveolin 1 - deficiency; Caveolin 1 - physiology; Cells, Cultured; Chemokines; Collagen; Disease Models, Animal; Diseases of the osteoarticular system; Female; Fibroblasts; Humans; Immune system; Inflammation; Kinases; Leukocytes - metabolism; Leukocytes - physiology; Lung diseases; Lungs; Male; Medical sciences; Mice; Middle Aged; Monocytes - drug effects; Monocytes - physiology; Mortality; Neutrophil Infiltration - drug effects; Neutrophils; Peptide Fragments - pharmacology; Peptides; Proteins; Pulmonary fibrosis; Pulmonary Fibrosis - chemically induced; Pulmonary Fibrosis - metabolism; Pulmonary Fibrosis - pathology; Scleroderma; Scleroderma, Systemic - metabolism; Scleroderma, Systemic - pathology; Signal Transduction - physiology; Young Adult; Lung disease; Regulation(control); Respiratory disease; Rheumatology

Objectives Reduced caveolin-1 levels in lung fibroblasts from patients with scleroderma and the lungs of bleomycin-treated mice promote collagen overexpression and lung fibrosis. This study was undertaken to determine whether caveolin-1 is deficient in leucocytes from bleomycin-treated mice and pati...